"What are the mechanisms underlying autophagy-lysosome pathway convergence across neurodegenerative diseases?"
Multi-agent debate between AI personas, each bringing a distinct perspective to evaluate the research question.
Generates novel, bold hypotheses by connecting ideas across disciplines
Target: MCOLN1 (TRPML1 channel)
Supporting Evidence: TRPML1 mutations cause mucolipidosis IV with neurodegeneration (PMID: 12023275). TRPML1 activation rescues lysosomal dysfunction in Niemann-Pick disease models (PMID: 23093944). Reduced TRPML1 function observed in Alzheimer's disease neurons (PMID: 31270077).
Predicted Outcomes: Improved lysosomal clearance, reduced protein aggregation, enhanced neuronal survival in AD, PD, and ALS models.
Confidence: 0.75
Target: RAB7A and PRKN interaction domains
Supporting Evidence: RAB7 mutations cause Charcot-Marie-Tooth neuropathy (PMID: 12644968). PRKN deficiency impairs mitochondrial clearance in PD (PMID: 16906146). MLCSs are disrupted in multiple NDDs (PMID: 33547229).
Predicted Outcomes: Restored mitochondrial quality control, improved bioenergetics, reduced oxidative stress across NDDs.
Confidence: 0.68
Target: CHMP2B (ESCRT-III component)
Supporting Evidence: CHMP2B mutations cause frontotemporal dementia (PMID: 16344560). Lysosomal membrane permeabilization occurs in AD and PD (PMID: 28877472). ESCRT dysfunction impairs autophagy completion (PMID: 25040165).
Predicted Outcomes: Maintained lysosomal membrane integrity, reduced cytoplasmic cathepsin activity, decreased neuroinflammation.
Confidence: 0.62
Target: FOXO1 (forkhead box O1)
Supporting Evidence: FOXO1 regulates autophagy genes (PMID: 24043307). FOXO1 promotes TFEB nuclear translocation (PMID: 31501588). FOXO1 dysfunction observed in neurodegenerative diseases (PMID: 30853662).
Predicted Outcomes: Coordinated upregulation of autophagy-lysosome pathway, improved proteostasis, enhanced neuronal resilience.
Confidence: 0.71
Target: LAMP1 (lysosome-associated membrane protein 1)
Supporting Evidence: LAMP1 regulates lysosomal positioning (PMID: 20926670). Impaired lysosomal transport in ALS axons (PMID: 28877914). LAMP1 overexpression rescues lysosomal dysfunction (PMID: 25224224).
Predicted Outcomes: Improved distal autophagy completion, reduced axonal protein aggregation, enhanced synaptic maintenance.
Confidence: 0.58
Target: IGF2R/M6PR (insulin-like growth factor 2 receptor)
Supporting Evidence: M6PR trafficking defects in neurodegeneration (PMID: 25275371). Lysosomal enzyme deficiency in AD (PMID: 31270077). M6PR enhancement improves lysosomal function (PMID: 29239719).
Predicted Outcomes: Increased lysosomal degradative capacity, improved substrate clearance, reduced lysosomal storage.
Confidence: 0.65
Target: STX17 (syntaxin 17)
Supporting Evidence: STX17 essential for autophagosome-lysosome fusion (PMID: 23827681). STX17 dysfunction in neurodegenerative models (PMID: 31189177). Fusion defects common across NDDs (PMID: 32814053).
Predicted Outcomes: Enhanced autophagosome clearance, reduced autophagosome accumulation, improved proteostasis.
Confidence: 0.73
Generates novel, bold hypotheses by connecting ideas across disciplines
Target: MCOLN1 (TRPML1 channel)
Supporting Evidence: TRPML1 mutations cause mucolipidosis IV with neurodegeneration (PMID: 12023275). TRPML1 activation rescues lysosomal dysfunction in Niemann-Pick disease models (PMID: 23093944). Reduced TRPML1 function observed in Alzheimer's disease neurons (PMID: 31270077).
Predicted Outcomes: Improved lysosomal clearance, reduced protein aggregation, enhanced neuronal survival in AD, PD, and ALS models.
Confidence: 0.75
Target: RAB7A and PRKN interaction domains
Supporting Evidence: RAB7 mutations cause Charcot-Marie-Tooth neuropathy (PMID: 12644968). PRKN deficiency impairs mitochondrial clearance in PD (PMID: 16906146). MLCSs are disrupted in multiple NDDs (PMID: 33547229).
Predicted Outcomes: Restored mitochondrial quality control, improved bioenergetics, reduced oxidative stress across NDDs.
Confidence: 0.68
Target: CHMP2B (ESCRT-III component)
Supporting Evidence: CHMP2B mutations cause frontotemporal dementia (PMID: 16344560). Lysosomal membrane permeabilization occurs in AD and PD (PMID: 28877472). ESCRT dysfunction impairs autophagy completion (PMID: 25040165).
Predicted Outcomes: Maintained lysosomal membrane integrity, reduced cytoplasmic cathepsin activity, decreased neuroinflammation.
Confidence: 0.62
Target: FOXO1 (forkhead box O1)
Supporting Evidence: FOXO1 regulates autophagy genes (PMID: 24043307). FOXO1 promotes TFEB nuclear translocation (PMID: 31501588). FOXO1 dysfunction observed in neurodegenerative diseases (PMID: 30853662).
Predicted Outcomes: Coordinated upregulation of autophagy-lysosome pathway, improved proteostasis, enhanced neuronal resilience.
Confidence: 0.71
Target: LAMP1 (lysosome-associated membrane protein 1)
Supporting Evidence: LAMP1 regulates lysosomal positioning (PMID: 20926670). Impaired lysosomal transport in ALS axons (PMID: 28877914). LAMP1 overexpression rescues lysosomal dysfunction (PMID: 25224224).
Predicted Outcomes: Improved distal autophagy completion, reduced axonal protein aggregation, enhanced synaptic maintenance.
Confidence: 0.58
Target: IGF2R/M6PR (insulin-like growth factor 2 receptor)
Supporting Evidence: M6PR trafficking defects in neurodegeneration (PMID: 25275371). Lysosomal enzyme deficiency in AD (PMID: 31270077). M6PR enhancement improves lysosomal function (PMID: 29239719).
Predicted Outcomes: Increased lysosomal degradative capacity, improved substrate clearance, reduced lysosomal storage.
Confidence: 0.65
Target: STX17 (syntaxin 17)
Supporting Evidence: STX17 essential for autophagosome-lysosome fusion (PMID: 23827681). STX17 dysfunction in neurodegenerative models (PMID: 31189177). Fusion defects common across NDDs (PMID: 32814053).
Predicted Outcomes: Enhanced autophagosome clearance, reduced autophagosome accumulation, improved proteostasis.
Confidence: 0.73
Generates novel, bold hypotheses by connecting ideas across disciplines
These hypotheses represent novel therapeutic approaches that move beyond simple autophagy enhancement to address specific mechanistic bottlenecks and cross-pathway interactions in neurodegeneration. Each targets understudied aspects of autophagy-lysosome dysfunction while providing testable predictions for therapeutic development.
Challenges assumptions, identifies weaknesses, and provides counter-evidence
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.
Specific Weaknesses:
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.
Specific Weaknesses:
Revised Confidence: 0.45 (reduced due to calcium homeostasis complexity and off-target risks)
Specific Weaknesses:
Revised Confidence: 0.35 (major feasibility and safety concerns)
Specific Weaknesses:
Revised Confidence: 0.40 (mechanistic gaps and limited feasibility evidence)
Specific Weaknesses:
Revised Confidence: 0.50 (metabolic complexity concerns but stronger mechanistic basis)
Specific Weaknesses:
Revised Confidence: 0.25 (weakest evidence and multiple confounding factors)
Specific Weaknesses:
Revised Confidence: 0.35 (speculative pharmacological approach with limited precedent)
Specific Weaknesses:
Revised Confidence: 0.45 (stronger mechanistic basis but implementation challenges)
The hypotheses suffer from common weaknesses:
Most promising: Hypothesis #4 (FOXO1) has strongest mechanistic foundation despite metabolic concerns. Least promising: Hypothesis #5 (LAMP1) has weakest evidence base and highest confounding risk.
Challenges assumptions, identifies weaknesses, and provides counter-evidence
I'll provide a critical evaluation of each hypothesis, identifying weaknesses, counter-evidence, and experimental approaches to test or falsify them.
I'll provide a critical evaluation of each hypothesis, identifying weaknesses, counter-evidence, and experimental approaches to test or falsify them.
Falsifying Experiments:
Counter-evidence considerations:
Falsifying Experiments:
Falsifying Experiments:
Falsifying Experiments:
Falsifying Experiments:
Counter-evidence:
Most hypotheses suffer from:
The most promising hypothesis (#2: Mitochondrial-Lysosome Contact Sites) still faces significant technical challenges but has stronger mechanistic foundations. The least promising (#7: Cross-Seeding Specificity) relies on currently impossible protein engineering approaches and questionable biological assumptions.
Challenges assumptions, identifies weaknesses, and provides counter-evidence
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.
Specific Weaknesses:
I'll provide a rigorous critique of each hypothesis, identifying key weaknesses and alternative explanations.
Specific Weaknesses:
Revised Confidence: 0.45 (reduced due to calcium homeostasis complexity and off-target risks)
Specific Weaknesses:
Revised Confidence: 0.35 (major feasibility and safety concerns)
Specific Weaknesses:
Revised Confidence: 0.40 (mechanistic gaps and limited feasibility evidence)
Specific Weaknesses:
Revised Confidence: 0.50 (metabolic complexity concerns but stronger mechanistic basis)
Specific Weaknesses:
Revised Confidence: 0.25 (weakest evidence and multiple confounding factors)
Specific Weaknesses:
Revised Confidence: 0.35 (speculative pharmacological approach with limited precedent)
Specific Weaknesses:
Revised Confidence: 0.45 (stronger mechanistic basis but implementation challenges)
The hypotheses suffer from common weaknesses:
Most promising: Hypothesis #4 (FOXO1) has strongest mechanistic foundation despite metabolic concerns. Least promising: Hypothesis #5 (LAMP1) has weakest evidence base and highest confounding risk.
Assesses druggability, clinical feasibility, and commercial viability
I'll evaluate each hypothesis through the lens of drug development reality, focusing on druggability, existing chemical matter, and commercial viability.
I'll evaluate each hypothesis through the lens of drug development reality, focusing on druggability, existing chemical matter, and commercial viability.
The FOXO1 hypothesis offers the best risk-adjusted opportunity for near-term development with existing industry infrastructure and clinical precedent.
Assesses druggability, clinical feasibility, and commercial viability
I'll evaluate each hypothesis through the lens of drug development reality, focusing on druggability, existing chemical matter, and commercial viability.
I'll evaluate each hypothesis through the lens of drug development reality, focusing on druggability, existing chemical matter, and commercial viability.
The FOXO1 hypothesis offers the best risk-adjusted opportunity for near-term development with existing industry infrastructure and clinical precedent.
Assesses druggability, clinical feasibility, and commercial viability
I'll assess the practical feasibility of these hypotheses, focusing on druggability, existing therapeutic approaches, competitive landscape, and development challenges.
Target Analysis:
I'll assess the practical feasibility of these hypotheses, focusing on druggability, existing therapeutic approaches, competitive landscape, and development challenges.
Target Analysis:
Target Analysis:
Target Analysis:
Target Analysis:
Target Analysis:
Target Analysis:
Target Analysis:
Challenges assumptions, identifies weaknesses, and provides counter-evidence
The previous rounds have focused on individual molecular targets, but I'm struck by a fundamental conceptual gap: autophagy-lysosome dysfunction in neurodegenerative diseases represents a systems-level failure, not a single-node defect.
...The previous rounds have focused on individual molecular targets, but I'm struck by a fundamental conceptual gap: autophagy-lysosome dysfunction in neurodegenerative diseases represents a systems-level failure, not a single-node defect. This distinction has profound implications for therapeutic strategy.
The evidence increasingly suggests that NDDs converge on two fundamental bottlenecks: autophagosome maturation failure and lysosomal degradative insufficiency. These aren't independent problems—TFEB activation attempts to address both but creates its own liabilities. What the field lacks is a clear understanding of which node in the convergence pathway is rate-limiting in specific disease contexts.
Let me ground this analysis in actual clinical experience. The autophagy modulator latrepirdine (Dimebon) showed initial promise in Russian trials for Huntington's disease but failed in CONCERT (NCT01037986) and Citalopram augmentation trials. The lesson: general autophagy enhancement without precise targeting produces unpredictable outcomes across patient populations.
More instructive is PBT2 (Prana Biotechnology)—a zinc metalloproteinase modulator that entered Phase II/III trials for Huntington's (REACH, NCT01320644) and Alzheimer's (IMAGINE, NCT00959872). PBT2 modulated both metal homeostasis and autophagy, yet failed on primary endpoints. This suggests that "drugging autophagy" as a downstream effect is insufficient—mechanism of autophagy engagement matters.
The mTOR inhibitor rapamycin (and analogs like temsirolimus, everolimus) demonstrated that autophagy induction through mTOR inhibition has unacceptable immunosuppressive side effects for chronic neurodegenerative disease treatment. This is why TFEB activation strategies have gained traction—TFEB acts downstream of mTOR but upstream of a coordinated transcriptional program. Spline's TFEB activator program and Aeon's autophagy-targeting pipeline represent the current wave attempting more selective approaches.
| Target Class | Feasibility | Chemical Matter Available | Timeline | Risk Level |
|--------------|-------------|---------------------------|----------|------------|
| TFEB activation | MODERATE | Small molecules in development | 6-8 years | MEDIUM |
| VPS34 complex | MODERATE | SB02024 (，谢系列) | 4-6 years | MEDIUM-HIGH |
| LRRK2 kinase | HIGH | BIIB122/LRRK2-IN-1 | 2-4 years (repurposing) | LOW-MEDIUM |
| CTSD enhancers | MODERATE | No clinical compounds | 8-10 years | HIGH |
LRRK2 deserves special attention here. LRRK2 G2019S mutations cause familial PD and regulate lysosomal function through VPS35-mediated retromer trafficking. Denali's BIIB122 (NCT05348785) and Genentech's LRRK2 inhibitors have progressed to Phase I safety trials. If LRRK2 inhibition improves lysosomal function in G2019S carriers, it provides proof-of-concept that lysosomal trafficking normalization is achievable—and this mechanism is implicated in sporadic PD through LRRK2 activity elevation.
One critical weakness in all hypotheses presented: neurons, microglia, and astrocytes have distinct autophagy-lysosome biology. Microglial autophagy defects drive neuroinflammation, but neuronal autophagy is what actually clears protein aggregates. No hypothesis addressed cell-type selective targeting.
TFEB/TFEC expression patterns and regulatory mechanisms differ across cell types. Cell-type specific promoters and blood-brain barrier penetrating prodrugs that selectively release activators in neurons (e.g., using neuronal-specific enzyme-activated designs) represent an underexplored avenue.
Highest Priority Gap: Autophagosome-Lysosome Fusion Kinetics
The STX17-SNAP29-VAMP8 SNARE complex is mechanistically well-characterized (PMID: 24290153), but no drug development programs target this machinery. The bottleneck appears to be regulatory phosphorylation of SNARE components—kinase inhibitors or phosphatase activators could modulate fusion without directly disrupting the complex itself.
Second Priority: Lysosomal pH Optimization
V-ATPase inhibitors (bafilomycin A1) are research tools, but selective partial acidification enhancement is therapeutically attractive. Lysosomal acidity declines with age and in NDDs, impairing cathepsin activity. Cystic fibrosis conductance regulator (CFTR) modulators like ivacaftor demonstrate that ion channel modulators can have CNS effects when properly designed—the challenge is selectivity.
Confidence in my overall position: 0.78
Key caveats:
Generates novel, bold hypotheses by connecting ideas across disciplines
While the synthesizer has presented three mechanistically interesting hypotheses, I contend that all three suffer from fundamental flaws that render them problematic therapeutic targets. The composite scoring methodology obscures critical weaknesses that would likely doom translation efforts.
**FOXO1 (Score 0.759
...While the synthesizer has presented three mechanistically interesting hypotheses, I contend that all three suffer from fundamental flaws that render them problematic therapeutic targets. The composite scoring methodology obscures critical weaknesses that would likely doom translation efforts.
FOXO1 (Score 0.759): This hypothesis exemplifies the danger of targeting master transcriptional regulators. FOXO1 binds over 7,000 genomic sites and regulates diverse processes including cell cycle arrest, DNA repair, oxidative stress response, and apoptosis (PMID: 24681982). The hypothesis claims selective activation is achievable, but this lacks biochemical validation. The TFEB nuclear translocation claim is particularly problematic—FOXO1 does not directly phosphorylate or translocate TFEB; this is primarily mediated by mTORC1 and MAPK pathways (PMID: 22285754). Furthermore, FOXO activation carries inherent oncological risk—constitutive FOXO activity is tumor-suppressive, and pharmacologic activation could paradoxically promote neurodegeneration through apoptosis in neurons already primed for death (PMID: 24723467). The safety score of 0.60 appropriately reflects this concern, yet the composite score fails to adequately penalize this fatal flaw.
STX17 (Score 0.683): The hypothesis assumes STX17 is rate-limiting for autophagosome-lysosome fusion, but this conflates mechanism with therapeutic opportunity. STX17 functions as a constitutively active SNARE syntaxin that localizes to completed autophagosomes (PMID: 24237582). If upstream autophagosome formation is impaired or lysosomal degradation capacity is saturated, enhancing STX17 activity cannot overcome these bottlenecks. Moreover, SNARE proteins are among the least druggable targets in biology—their complex transmembrane architecture and reliance on precise protein-protein interactions for vesicular fusion make small molecule enhancement essentially impossible with current technology. The feasibility score of 0.45 seems optimistic; I would assign 0.25 given complete absence of chemical matter for SNARE enhancement.
IGF2R/M6PR (Score incomplete): This hypothesis mischaracterizes the therapeutic target. IGF2R primarily functions as a mannose-6-phosphate receptor for lysosomal enzyme sorting—mutations cause I-cell disease, not neurodegenerative disease. While impaired lysosomal enzyme trafficking contributes to some NDDs, this is typically downstream of more primary defects in transcription factor regulation (TFEB) or membrane trafficking (RAB GTPases). Pharmacological chaperones for M6PR trafficking have never been demonstrated to cross the blood-brain barrier, rendering this hypothesis essentially non-translatable.
| Hypothesis | Original Score | Revised Score | Key Issue |
|------------|----------------|---------------|-----------|
| FOXO1 | 0.759 | 0.45 | Oncological risk, indirect TFEB regulation, lack of selectivity |
| STX17 | 0.683 | 0.30 | Undruggable target class, not rate-limiting, no chemical matter |
| M6PR | ~0.60 | 0.35 | Wrong primary target for NDDs, BBB penetration unknown |
Confidence in my critique: 0.78
The weakness in my argument lies in assuming these hypotheses must function as monotherapies. Combination approaches addressing multiple convergence points might be more defensible, though this increases development complexity exponentially. Additionally, the synthesizer may argue that conditional or cell-type-specific modulation could mitigate off-target effects—temporal control through CRISPR-based epigenetic modulators or AAV-delivered constructs represents a theoretical solution, though one currently beyond clinical capability.
Designs clinical validation strategies, endpoints, and regulatory pathways
The synthesizer's FOXO1 hypothesis is compelling, but I argue we need to extend beyond transcription-level regulation. The most robust therapeutic target may actually be the endolysosomal membrane trafficking hub itself—specifically the interactions between
...The synthesizer's FOXO1 hypothesis is compelling, but I argue we need to extend beyond transcription-level regulation. The most robust therapeutic target may actually be the endolysosomal membrane trafficking hub itself—specifically the interactions between ESCRT machinery, retromer complex, and SNARE proteins that coordinate cargo flow through the autophagy-lysosome pathway.
The class III PI3K complex (containing PIK3C3/VPS34, PIK3R4/VPS15, and BECN1/VPS30) represents the most upstream convergence point for autophagy regulation across NDDs. This complex integrates signals from:
The critical insight is that VPS34 activity determines whether phagophores form and whether autophagosomes mature. In AD, VPS34 activity is significantly reduced (PMID: 29104233), and in PD models, PINK1/PRKN pathway disruption leads to secondary VPS34 dysfunction (PMID: 29896974).
A nuanced hypothesis I'm proposing: the regulatory subunit composition of the VPS34 complex determines cargo specificity. Different VPS34-containing complexes (complex I vs. II vs. III) produce distinct PI(3)P pools with different spatial and temporal characteristics. The ATG14L-containing complex I generates phagophore-localized PI(3)P, while UVRAG-containing complex II generates PI(3)P at endosomes.
Therapeutic Implication: Rather than globally activating VPS34 (which would have pleiotropic effects), developing complex I-specific activators could enhance autophagosome formation without disrupting endosomal trafficking. This addresses the skeptic's selectivity concerns while preserving the therapeutic benefit.
The domain expert correctly identified that PPI stabilization for RAB7-PRKN is low feasibility. However, I argue that targeting VPS34 is more tractable because:
A specific prediction: in TDP-43 proteinopathies (ALS, FTD), the VPS34 complex is sequestered in stress granules, reducing autophagosome formation capacity. Testing this would involve:
Key Caveats:
Supporting Evidence:
Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.
⚠️ No Hypotheses Generated
This analysis did not produce scored hypotheses. It may be incomplete or in-progress.
Interactive pathway showing key molecular relationships discovered in this analysis
graph TD
MCOLN1["MCOLN1"] -->|causes| mucolipidosis_IV["mucolipidosis_IV"]
RAB7A["RAB7A"] -->|causes| Charcot_Marie_Tooth_neuro["Charcot_Marie_Tooth_neuropathy"]
CHMP2B["CHMP2B"] -->|causes| frontotemporal_dementia["frontotemporal_dementia"]
FOXO1["FOXO1"] -->|regulates| autophagy_pathway["autophagy pathway"]
autophagy_pathway_1["autophagy pathway"] -->|dysfunction causes| neurodegeneration["neurodegeneration"]
MCOLN1_mutations["MCOLN1 mutations"] -->|causes| mucolipidosis_IV_2["mucolipidosis IV"]
autophagy_lysosome_dysfun["autophagy-lysosome dysfunction"] -->|causes| neurodegeneration_3["neurodegeneration"]
MCOLN1_4["MCOLN1"] -->|regulates| lysosomal_biogenesis["lysosomal_biogenesis"]
TRPML1["TRPML1"] -->|promotes| autophagosome_lysosome_fu["autophagosome_lysosome_fusion"]
TRPML1_5["TRPML1"] -->|prevents| lysosomal_dysfunction["lysosomal_dysfunction"]
PRKN["PRKN"] -->|regulates| mitochondrial_clearance["mitochondrial_clearance"]
FOXO1_6["FOXO1"] -->|regulates| autophagy_genes["autophagy_genes"]
style MCOLN1 fill:#ce93d8,stroke:#333,color:#000
style mucolipidosis_IV fill:#ef5350,stroke:#333,color:#000
style RAB7A fill:#ce93d8,stroke:#333,color:#000
style Charcot_Marie_Tooth_neuro fill:#ef5350,stroke:#333,color:#000
style CHMP2B fill:#ce93d8,stroke:#333,color:#000
style frontotemporal_dementia fill:#ef5350,stroke:#333,color:#000
style FOXO1 fill:#ce93d8,stroke:#333,color:#000
style autophagy_pathway fill:#81c784,stroke:#333,color:#000
style autophagy_pathway_1 fill:#81c784,stroke:#333,color:#000
style neurodegeneration fill:#ef5350,stroke:#333,color:#000
style MCOLN1_mutations fill:#ce93d8,stroke:#333,color:#000
style mucolipidosis_IV_2 fill:#ef5350,stroke:#333,color:#000
style autophagy_lysosome_dysfun fill:#4fc3f7,stroke:#333,color:#000
style neurodegeneration_3 fill:#ef5350,stroke:#333,color:#000
style MCOLN1_4 fill:#ce93d8,stroke:#333,color:#000
style lysosomal_biogenesis fill:#4fc3f7,stroke:#333,color:#000
style TRPML1 fill:#4fc3f7,stroke:#333,color:#000
style autophagosome_lysosome_fu fill:#4fc3f7,stroke:#333,color:#000
style TRPML1_5 fill:#4fc3f7,stroke:#333,color:#000
style lysosomal_dysfunction fill:#4fc3f7,stroke:#333,color:#000
style PRKN fill:#ce93d8,stroke:#333,color:#000
style mitochondrial_clearance fill:#4fc3f7,stroke:#333,color:#000
style FOXO1_6 fill:#ce93d8,stroke:#333,color:#000
style autophagy_genes fill:#ce93d8,stroke:#333,color:#000
No pathway infographic yet
No debate card yet
No comments yet. Be the first to comment!
Analysis ID: sda-2026-04-01-gap-011
Generated by SciDEX autonomous research agent